[Multidisciplinary expert consensus for clinical application of mineralocorticoid receptor antagonists in China].

Mineralocorticoid receptor antagonists (MRAs) inhibit the overactivation of mineralocorticoid receptors (MRs), resulting in potassium retention and diuresis, and are widely used in clinical practice. They were classified into steroidal MRAs (such as spironolactone and eplerenone) and new nonsteroidal MRAs (such as finerenone) according to the molecular structure. Three most commonly used MRs are clinically available at present, spironolactone, eplerenone and finerenone. The efficacy and safety of the three drugs differ from each in the treatment of chronic kidney disease, heart failure, hypertension and other diseases. It is, thus, of great necessary to reach a multidisciplinary expert consensus on the clinical practice of MRAs to improve the understanding of medical workers in China on steroidal and nonsteroidal MRAs, and help them with rational administration of the drugs.盐皮质激素受体拮抗剂（MRA）能够抑制盐皮质激素受体的过度激活，在临床上可用于多种慢性疾病的治疗。根据分子结构，MRA可分为传统的甾体类（如螺内酯和依普利酮）和新一代的非甾体类（如非奈利酮等）。目前临床使用较多的3种MRA为螺内酯、依普利酮和非奈利酮，在治疗慢性肾脏病、心力衰竭和高血压等疾病的疗效和安全性方面均有所区别。本共识旨在进一步提高临床医师对甾体类及非甾体类MRA的认识，有助于合理选择及应用MRA。.